Erratum: Economic impact of a genetic test for cisplatin-induced ototoxicity (The Pharmacogenomics Journal (2012) 12 (205-213) DOI: 10.1038/tpj.2011.15);Economic impact of a genetic test for cisplatin-induced ototoxicity

Pharmacogenomics Journal

Volumn 12, Issue 3, 2012, Pages 205-213

  Dionne, F ^a   Mitton, C ^a   Rassekh, R ^a   Brooks, B ^a   Ross, C ^a   Hayden, M ^a   Carleton, B ^a  

^a Research Pavilion   (Canada)

Author keywords

cisplatin; costs; genetic test; hearing loss; ototoxicity

Indexed keywords

AMIFOSTINE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; OXOPLATIN; PICOPLATIN;

ADOLESCENT; ADULT; ARTICLE; BRAIN TUMOR; CANADA; CHILD; CHILDHOOD CANCER; COST CONTROL; DRUG RESPONSE; FEMALE; GENETIC SCREENING; GERM CELL TUMOR; HEALTH CARE COST; HEALTH ECONOMICS; HEARING LOSS; HEPATOBLASTOMA; HUMAN; INFANT; MALE; NEUROBLASTOMA; OSTEOSARCOMA; OTOTOXICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; UNSPECIFIED SIDE EFFECT;

EID: 85027924873     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.21     Document Type: Erratum

References (27)

1. Dhooge I, Dhooge C, Geukens S, De Clerk B, De Vel E, Vinck B. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with cisplatin. Int J Audiol 2006; 45: 337-343. (Pubitemid 44576328)
2. van den Berg JH, Beijnen JH, Balm AJM, Schellens JHM. Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat Rev 2006; 32: 390-397. (Pubitemid 44063878)
3. Li Y, Womer RB, Silber J. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer 2004; 40: 2445-2451. (Pubitemid 39424959)
4. Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol 2007; 29: 355-360. (Pubitemid 46884215)
5. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005; 23: 8588-8596. (Pubitemid 46211500)
6. Kushner BH, Budnick A, Kramer K, Modak S, Cheung NK. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 2006; 107: 417-422. (Pubitemid 44036572)
7. Schroeder L, Petrou S, Kennedy C, McCann D, Law C, Watkin PM et al. The economic costs of congenital bilateral permanent childhood hearing impairment. Pediatrics 2006; 117: 1101-1112. (Pubitemid 46071501)
8. Ross CJD, Katzov-Eckert H, Dubé M-P, Brooks B, Rassekh SR, Barhdadi A et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009; 41: 1345-1349.
9. Bank of Canada. Inflation calculator. Retrieved at: http://www. bankofcanada.ca/en/rates/inflation-calc.html.
10. Mohr PE, Feldman JJ, Dunbar JL, McConkey-Robbins A, Niparko JK, Rittenhouse RK et al. The societal costs of severe to profound hearing loss in the United States. Int J Technol Assess Health Care 2000; 16: 1120-1135.
11. Statistics Canada. Average earnings by sex and work pattern. Retrieved at: http://www40.statcan.ca/l01/cst01/labor01a-eng.htm.
12. Centers for Disease Control Prevention (CDC). Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment-United States. Morb Mortal Wkly Rep 2004; 53: 57-59.
13. Canadian Cancer Society. Canadian Cancer Statistics 2009. 2009 Retrieved at: http://www.cancer.ca/B/media/CCS/Canada%20wide/Files%20List/ English%20files%20heading/pdf%20not%20in%20publications%20section/ Stats%202009E%20Cdn%20Cancer.ashx.
14. Phillips B, Powers BE, Dernell WS, Straw RC, Khanna C, Hogge GS et al. Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs. J Am Anim Hosp Assoc 2009; 45: 33-38.
15. Robson H, Meyer S, Shalet SM, Anderson E, Roberts S, Eden OB. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines. Med Pediatr Oncol 2002; 39: 573-580. (Pubitemid 35191440)
16. Simon T, Hero B, Dupuis W, Selle B, Berthold F. The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Padiatr 2002; 214: 149-152. (Pubitemid 34925488)
17. Mann JR, Raafat F, Robinson K, Imeson J, Gornall P, Sokal M et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol 2000; 18: 3809-3818.
18. Haberle B, Bode U, Von Schweinitz D. Differentiated treatment protocols for high- and standard-risk hepatoblastoma-an interim report of the German Liver Tumor Study HB99. Klin Padiatr 2003; 215: 159-165. (Pubitemid 36718288)
19. Fouladi M, Chintagumpala M, Ashley D, Kellie S, Gururangan S, Hassall T et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol 2008; 26: 3749-3755.
20. Papsin BC, Gordon KA. Cochlear implants for children with severe-toprofound hearing loss. N Engl J Med 2007; 357: 2380-2387.
21. Snik FM, van Duijnhoven NTL, Mylanus EAM, Cremers WRJ. Estimated cost-effectiveness of active middle-ear implantation in hearing-impaired patients with severe external otitis. Arch Otolaryngol Head Neck Surg 2006; 132: 1210-1215. (Pubitemid 44800134)
22. For Deaf People (fdp) 2010##Social impact of hearing loss. Retrieved at: http://www.fdp.org.uk/articles/social-impact.html.
23. Fellinger J, Holzinger D, Sattel H, Laucht M. Mental health and quality of life in deaf pupils. Eur Child Adolesc Psychiatry 2008; 17: 414-423.
24. Hallam R, Ashton P, Sherbourne K, Gailey L. Persons with acquired profound hearing loss (APHL): how do they and their families adapt to the challenge? Health 2008; 12: 369-388.
25. Mason A, Mason M. Psychologic impact of deafness on the child and adolescent. Prim Care 2007; 34: 407-426. (Pubitemid 47102405)
26. Berk L. Emotional and social development in adolescence. In: Development Through the Lifespan, 2nd edn Allyn & Bacon: Needham Heights, MA, 2001, pp 388-417.
27. The Lancet. Taking childhood hearing loss seriously. Lancet 2007; 369: 1234.